Spastic Diplegia and Other Motor Disturbances in Infants Receiving Interferon‐Alpha

Michaud, André Paul; Bauman, Nancy M.; Burke, Diane K.; Manaligod, José R.; Smith, Richard J.H.

doi:10.1097/00005537-200407000-00017

Cited by 129 publications

(68 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other treatment options for problematic IH include intra-lesional corticosteroids, vincristine, interferonalpha, cyclophosphamide, laser, surgery or a combination of these therapies. However, each of these modalities has limited therapeutic benefit with its own side-effect profile and potential serious risks [2,15].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas

et al. 2010

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Interferon-α has proven to be effective, but potential neurotoxicity -specifically, spastic diplegia -has limited its use. 68 Vincristine also has been tried for aggressive, complicated IHs resistant to other therapies. In addition, there are some reports of cyclophosphamide use in the pediatric hematology-oncology literature for the treatment of lifethreatening diffuse neonatal hemangiomatosis.…”

Section: Treatmentmentioning

confidence: 99%

Infantile hemangiomas: from pathogenesis to clinical features

Rosenblatt¹,

Mathes²,

Rosbe

2012

RRN

View full text Add to dashboard Cite

Infantile hemangiomas (IH) are benign vascular tumors consisting of a collection of immature cells, including progenitor stem cells and disorganized blood vessels. They are the most common benign tumors in childhood. Recently, there have been significant, exciting advancements in the understanding of the pathogenesis and treatment of infantile hemangiomas, which are discussed in this review. The decision to initiate treatment for IH is based on many factors, including size and location, functional compromise, psychosocial implications, and risks and benefits of the proposed therapy. For most families of children with hemangiomas, education about the natural history of IH and reassurance are often the only "treatment" required. A minority of patients with large, complex lesions or lesions that cause functional compromise require early intervention. These patients and families benefit from a multidisciplinary approach to care in vascular birthmark centers. Ongoing multi-institutional clinical trials will provide further important data on the efficacy and safety of hemangioma treatments.

show abstract

“…Spastic diplegia has been reported, especially when this medication is used in children under 1 year of age. 171 IFNa2b is approved by the FDA for the treatment of condyloma acuminata, chronic hepatitis B and C, hairy cell leukemia, malignant melanoma, AIDS-related KS, and follicular non-Hodgkin lymphoma. This treatment has been used to treat infantile hemangiomas, usually concurrently with corticosteroids or in the event of corticosteroid resistance 172,173 ; however, use of this therapy has been limited because of the risk of spastic diplegia.…”

Section: Interferon-alfa2bmentioning

confidence: 99%